HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AB&B BIO-TECH-B

29.320

0.000

Volume:- -

Turnover:- -

Market Cap:11.52B

PE:-34.96

High:29.320

Open:29.320

Low:29.320

Close:29.320

52wk High:73.000

52wk Low:28.880

Shares:393.00M

HK Float Shares:296.36M

Volume Ratio:0.51

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.839

ROE:--

ROA:--

PB:293.39

PE(LYR):-34.96

PS:30.50

Loading ...

Overview Company News Filings

AB&B BIO-TECH-B (02627) Achieves Milestone with Accepted Mpox mRNA Vaccine Application and Strategic Partnership with Chongqing CDC

AB&B Bio-Tech shares on Hong Kong Stock Exchange suspended pending delayed annual results

AB&B BIO-TECH-B (02627) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Audited Results and Consider Final Dividend

Bulletin Express

AB&B Bio-Tech sets board meeting to approve audited annual results and consider final dividend

Ab&B Bio-Tech Strikes Overseas Vaccine Deal With Walvax Hong Kong; Shares Fall 13%

MT Newswires Live

AB&B BIO-TECH-B Enters Strategic Pact with Hong Kong Watson for Overseas Market Expansion of Subunit Flu Vaccine

AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine

Bulletin Express

AB&B BIO-TECH-B (02627) Enters Strategic Pact with Hong Kong Watson for Overseas Expansion of Subunit Flu Vaccine

AB&B Bio-Tech signs strategic cooperation agreement with Walvax Hong Kong for overseas flu vaccine expansion

Ab&B Bio Tech - Enters Strategic Cooperation Agreement With Walvax Hong Kong Ltd

THOMSON REUTERS

Ab&B Bio Tech Co Ltd Js - Core Product for Expansion Is Trivalent Subunit Influenza Vaccine Huierkangxin 3

THOMSON REUTERS

AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine

AB&B BIO-TECH-B (02627) Activates Second Growth Engine with Impending Commercial Scale-Up and Pipeline Milestones

AB&B BIO-TECH-B (02627) Gains FDA IND Approval for mRNA Mpox Vaccine

Bulletin Express

AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Receives FDA Clearance for Clinical Trials

U.S. FDA Approves IND for AB&B Bio-Tech mRNA Mpox Vaccine Candidate

Ab&B Bio Tech Co Ltd Js - Ind Approval by U.S. FDA for Mrna Mpox Vaccine

THOMSON REUTERS

Ab&B Bio-Tech (02627) Reports Monthly Return for February 2026

Bulletin Express

Innovative Differentiation and Positive Earnings Forecast Set Stage for Davis Double at AB&B BIO-TECH-B (02627)

Ab&B Bio-Tech (2627) Reports Significant Revenue Growth and Reduced Net Loss for FY2025

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02627/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"AB&B BIO-TECH-B","latestPrice":29.32,"timestamp":1787275207144,"preClose":29.32,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":296361845,"shares":393000000,"eps":-0.8385895589238526,"marketStatus":"Halted","change":0,"latestTime":"08-21 09:20:07","open":29.32,"high":29.32,"low":29.32,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.7293047071646448,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":29.32,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5100838100119135,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.83859,"volumeRatio":0.5100838100119135,"shares":393000000,"dividePrice":0,"high":29.32,"amplitude":0,"preClose":29.32,"low":29.32,"week52Low":28.88,"pbRate":"293.39","psRate":"30.50","week52High":73,"institutionHeld":0,"latestPrice":29.32,"eps":-0.8385895589238526,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.7293047071646448,"open":29.32,"prevYearClose":40.24,"prevWeekClose":29.32,"prevMonthClose":29.32,"prevQuarterClose":29.32,"fiveDayClose":29.32,"twentyDayClose":29.32,"sixtyDayClose":29.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2026-03-31","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774920600000,"name":null,"time":"","dateTimestamp":1774886400000,"actualEps":null},{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2026-08-21","current":-40.202675,"percent":0.988142,"low":-109.844469,"twenty":-74.600848,"median":-63.899985,"eighty":-44.518459,"high":-18.07815,"avg":-59.988502,"sd":14.538107,"marketCap":11535737032},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-12","current":-62.655098,"twenty":-66.251138,"median":-63.08644,"eighty":-59.27469,"marketCap":19380982476},{"date":"2025-09-19","current":-81.048551,"twenty":-68.315951,"median":-63.912829,"eighty":-59.882299,"marketCap":19888523430},{"date":"2025-09-26","current":-77.095946,"twenty":-77.153546,"median":-65.395346,"eighty":-60.155426,"marketCap":18869507096},{"date":"2025-10-03","current":-76.784092,"twenty":-77.86406,"median":-66.074095,"eighty":-61.128611,"marketCap":18838031688},{"date":"2025-10-10","current":-75.450727,"twenty":-78.338288,"median":-66.623148,"eighty":-61.710077,"marketCap":18483933348},{"date":"2025-10-17","current":-70.044793,"twenty":-77.841467,"median":-68.315951,"eighty":-62.332762,"marketCap":17146228508},{"date":"2025-10-24","current":-70.694139,"twenty":-77.356453,"median":-69.86748,"eighty":-62.632094,"marketCap":17311474400},{"date":"2025-10-31","current":-64.652972,"twenty":-77.130506,"median":-68.586563,"eighty":-62.679826,"marketCap":15855736780},{"date":"2025-11-07","current":-65.014442,"twenty":-77.0495,"median":-67.012733,"eighty":-63.012535,"marketCap":15934425300},{"date":"2025-11-14","current":-69.152784,"twenty":-76.901535,"median":-66.692171,"eighty":-63.572329,"marketCap":16996720320},{"date":"2025-11-21","current":-64.47659,"twenty":-76.671062,"median":-66.251138,"eighty":-63.813259,"marketCap":15839999076},{"date":"2025-11-28","current":-66.221916,"twenty":-76.081201,"median":-65.883561,"eighty":-63.948664,"marketCap":16327867900},{"date":"2025-12-05","current":-64.387851,"twenty":-75.140133,"median":-65.711289,"eighty":-64.052768,"marketCap":15902949892},{"date":"2025-12-12","current":-65.09579,"twenty":-74.230454,"median":-65.51992,"eighty":-64.060512,"marketCap":16107540044},{"date":"2025-12-19","current":-64.75238,"twenty":-73.314016,"median":-65.09579,"eighty":-64.128623,"marketCap":16060326932},{"date":"2025-12-24","current":-63.88714,"twenty":-72.937878,"median":-65.019631,"eighty":-64.128296,"marketCap":15895081040},{"date":"2026-01-02","current":-63.38466,"twenty":-72.68164,"median":-64.955716,"eighty":-63.907691,"marketCap":15832130224},{"date":"2026-01-09","current":-64.42138,"twenty":-72.421694,"median":-64.920623,"eighty":-63.984499,"marketCap":16131146600},{"date":"2026-01-16","current":-79.012958,"twenty":-72.68164,"median":-65.002626,"eighty":-63.984499,"marketCap":19849179170},{"date":"2026-01-23","current":-80.264585,"twenty":-74.684429,"median":-65.09579,"eighty":-64.012742,"marketCap":20144261120},{"date":"2026-01-30","current":-75.685884,"twenty":-76.499114,"median":-65.441715,"eighty":-64.034272,"marketCap":19081966100},{"date":"2026-02-06","current":-72.661412,"twenty":-75.84841,"median":-65.678772,"eighty":-64.110439,"marketCap":18365900568},{"date":"2026-02-13","current":-79.706332,"twenty":-76.558032,"median":-65.817553,"eighty":-64.12895,"marketCap":20262293900},{"date":"2026-02-20","current":-82.611175,"twenty":-76.790716,"median":-65.857422,"eighty":-64.132361,"marketCap":20970490580},{"date":"2026-02-27","current":-82.941496,"twenty":-77.55936,"median":-66.221916,"eighty":-64.146544,"marketCap":21285244660},{"date":"2026-03-06","current":-81.374491,"twenty":-78.249638,"median":-66.33369,"eighty":-64.163416,"marketCap":20714752890},{"date":"2026-03-13","current":-88.155391,"twenty":-78.824484,"median":-66.830053,"eighty":-64.221195,"marketCap":22544260980},{"date":"2026-03-20","current":-60.352659,"twenty":-78.705126,"median":-66.485266,"eighty":-64.132361,"marketCap":15375736808},{"date":"2026-03-27","current":-47.779776,"twenty":-78.691316,"median":-66.244034,"eighty":-64.004997,"marketCap":12141638636},{"date":"2026-04-02","current":-45.178314,"twenty":-78.677046,"median":-65.897052,"eighty":-63.746879,"marketCap":11535737032},{"date":"2026-04-10","current":-44.832534,"twenty":-78.441179,"median":-65.857422,"eighty":-63.430885,"marketCap":11535737032},{"date":"2026-04-17","current":-44.813717,"twenty":-78.181043,"median":-65.711289,"eighty":-63.227242,"marketCap":11535737032},{"date":"2026-04-24","current":-44.811176,"twenty":-78.060991,"median":-65.51992,"eighty":-62.332762,"marketCap":11535737032},{"date":"2026-04-30","current":-44.783221,"twenty":-78.021843,"median":-65.28076,"eighty":-60.389723,"marketCap":11535737032},{"date":"2026-05-08","current":-44.644729,"twenty":-77.873074,"median":-65.02482,"eighty":-59.352088,"marketCap":11535737032},{"date":"2026-05-15","current":-44.527613,"twenty":-77.457906,"median":-64.955716,"eighty":-54.162029,"marketCap":11535737032},{"date":"2026-05-22","current":-44.62961,"twenty":-77.130506,"median":-64.865742,"eighty":-48.015114,"marketCap":11535737032},{"date":"2026-05-29","current":-44.474957,"twenty":-77.072723,"median":-64.7737,"eighty":-45.186782,"marketCap":11535737032},{"date":"2026-06-05","current":-44.410504,"twenty":-76.942339,"median":-64.709555,"eighty":-44.836445,"marketCap":11535737032},{"date":"2026-06-12","current":-44.440563,"twenty":-76.790716,"median":-64.652972,"eighty":-44.816847,"marketCap":11535737032},{"date":"2026-06-18","current":-44.334195,"twenty":-76.784092,"median":-64.606806,"eighty":-44.811176,"marketCap":11535737032},{"date":"2026-06-26","current":-44.551763,"twenty":-76.501517,"median":-64.559082,"eighty":-44.783221,"marketCap":11535737032},{"date":"2026-07-03","current":-44.518459,"twenty":-76.499114,"median":-64.484566,"eighty":-44.746029,"marketCap":11535737032},{"date":"2026-07-10","current":-44.573161,"twenty":-76.047687,"median":-64.42138,"eighty":-44.683785,"marketCap":11535737032},{"date":"2026-07-17","current":-44.415099,"twenty":-75.735703,"median":-64.384175,"eighty":-44.631174,"marketCap":11535737032},{"date":"2026-07-24","current":-44.405121,"twenty":-75.569622,"median":-64.258799,"eighty":-44.611538,"marketCap":11535737032},{"date":"2026-07-31","current":-44.320924,"twenty":-75.486659,"median":-64.151322,"eighty":-44.575108,"marketCap":11535737032},{"date":"2026-08-07","current":-44.235034,"twenty":-75.015399,"median":-64.128705,"eighty":-44.551763,"marketCap":11535737032},{"date":"2026-08-14","current":-44.179104,"twenty":-74.694617,"median":-64.015323,"eighty":-44.527613,"marketCap":11535737032},{"date":"2026-08-21","current":-44.081684,"twenty":-74.600848,"median":-63.899985,"eighty":-44.518459,"marketCap":11535737032}],"updateTime":1787481908946},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192791194","title":"AB&B BIO-TECH-B (02627) Achieves Milestone with Accepted Mpox mRNA Vaccine Application and Strategic Partnership with Chongqing CDC","url":"https://stock-news.laohu8.com/highlight/detail?id=1192791194","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192791194?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:40","pubTimestamp":1775004033,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has recently announced multiple breakthrough developments in its corporate innovation efforts. The clinical trial application for its independently developed Class 1 new drug,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159646","02627","BK1161","159261"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524665","title":"AB&B Bio-Tech shares on Hong Kong Stock Exchange suspended pending delayed annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524665","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624524665?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:33","pubTimestamp":1775003631,"startTime":"0","endTime":"0","summary":"Trading in AB&B Bio-Tech shares  on Hong Kong Stock Exchange will be suspended from 9:00 a.m. on April 1, 2026.Hong Kong Stock Exchange triggered the halt under Listing Rules requirement tied to delayed publication of fiscal 2025 annual results.Audit remains incomplete due to ongoing review of certain fund investments plus consultancy payments.Board meeting slated for March 31 to consider annual results release was postponed to a date to be announced.Trading will remain halted until AB&B Bio-Tech publishes its fiscal 2025 annual results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL16qjS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144477582","title":"AB&B BIO-TECH-B (02627) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Audited Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1144477582","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144477582?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:22","pubTimestamp":1773912143,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (stock code: 02627, “AB&B BIO-TECH-B”) announced that its Board of Directors will convene on 31 March 2026. The agenda includes: 1. Review and approval of the audited...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620439762","title":"AB&B Bio-Tech sets board meeting to approve audited annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620439762","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620439762?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:09","pubTimestamp":1773911362,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech will hold a board meeting on March 31, 2026 to consider and approve its audited annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbdYHF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619438766","title":"Ab&B Bio-Tech Strikes Overseas Vaccine Deal With Walvax Hong Kong; Shares Fall 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619438766","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619438766?lang=en_us&edition=fundamental","pubTime":"2026-03-16 11:10","pubTimestamp":1773630634,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech  said it has entered into a cooperation agreement with Walvax Hong Kong to expand overseas markets for its subunit influenza vaccine, according to a March 13 Hong Kong bourse filing.Shares of the biotech firm were down more than 13% in Monday morning trade.The companies will cooperate on overseas registration, sales, and commercialization of the group's products, with the trivalent subunit influenza vaccine Huierkangxin 3 as the core product for international expansion.The partnership will leverage Walvax Hong Kong's overseas market resources and distribution networks to accelerate expansion into Southeast Asia, Latin America, the Middle East, and other Southern Hemisphere markets.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177465844","title":"AB&B BIO-TECH-B Enters Strategic Pact with Hong Kong Watson for Overseas Market Expansion of Subunit Flu Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1177465844","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177465844?lang=en_us&edition=fundamental","pubTime":"2026-03-15 16:00","pubTimestamp":1773561654,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company has entered into a strategic cooperation agreement with Watson Biotech (Hong Kong) Limited concerning the overseas market expansion of a subunit...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129349142","title":"AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1129349142","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129349142?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:03","pubTimestamp":1773396227,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175657066","title":"AB&B BIO-TECH-B (02627) Enters Strategic Pact with Hong Kong Watson for Overseas Expansion of Subunit Flu Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1175657066","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175657066?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:54","pubTimestamp":1773395664,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company has entered into a strategic cooperation agreement with Watson Biotech (Hong Kong) Limited concerning the overseas market expansion of a subunit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619198027","title":"AB&B Bio-Tech signs strategic cooperation agreement with Walvax Hong Kong for overseas flu vaccine expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198027","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198027?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:46","pubTimestamp":1773395172,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech entered a strategic cooperation agreement with Walvax Hong Kong to support overseas market registration and commercialization of AB&B Bio-Tech’s products. The collaboration focuses on AB&B Bio-Tech’s trivalent subunit influenza vaccine Huierkangxin 3, which was approved for marketing in January 2026. The agreement targets expansion into markets including Southeast Asia, Latin America, and the Middle East. Walvax Hong Kong is a wholly owned subsidiary of Walvax Biotech.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 13, 2026, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL1LWc5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0046","02627","BK0239","BK1161","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619198062","title":"Ab&B Bio Tech - Enters Strategic Cooperation Agreement With Walvax Hong Kong Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198062?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:45","pubTimestamp":1773395159,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40022P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619198025","title":"Ab&B Bio Tech Co Ltd Js - Core Product for Expansion Is Trivalent Subunit Influenza Vaccine Huierkangxin 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198025?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:45","pubTimestamp":1773395159,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40022P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146910619","title":"AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1146910619","media":"Stock News","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146910619?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:25","pubTimestamp":1773041110,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) saw its shares rise more than 7% during the late trading session. At the time of writing, the stock was up 7.31%, trading at HK$56.5, with a turnover of HK$87.528 million. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","LABU","BK1161","02627","BK4585","159646","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102287845","title":"AB&B BIO-TECH-B (02627) Activates Second Growth Engine with Impending Commercial Scale-Up and Pipeline Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1102287845","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102287845?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:44","pubTimestamp":1772617474,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has recently announced two significant positive developments, drawing market attention. On one hand, the company's self-developed trivalent influenza virus subunit vaccine,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125468083","title":"AB&B BIO-TECH-B (02627) Gains FDA IND Approval for mRNA Mpox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1125468083","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125468083?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:04","pubTimestamp":1772615047,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co., Ltd. JS (AB&B Bio-Tech-B (02627)) announced that the U.S. Food and Drug Administration approved the Investigational New Drug application for its self-developed mRNA mpox vaccine...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198328209","title":"AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Receives FDA Clearance for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1198328209","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198328209?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:40","pubTimestamp":1772613621,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that in the United States, the Food and Drug Administration (FDA) has permitted the Investigational New Drug (IND) application for the group's self-developed mRNA...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616958093","title":"U.S. FDA Approves IND for AB&B Bio-Tech mRNA Mpox Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616958093","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616958093?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:33","pubTimestamp":1772613191,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS said the U.S. Food and Drug Administration has approved its Investigational New Drug application for a self-developed mRNA mpox vaccine candidate, allowing the program to proceed to clinical development in the United States. The company stated this is China’s first and the world’s third mRNA mpox vaccine candidate to receive FDA IND approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLb8tw1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616607580","title":"Ab&B Bio Tech Co Ltd Js - Ind Approval by U.S. FDA for Mrna Mpox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2616607580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616607580?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:32","pubTimestamp":1772613179,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124130150","title":"Ab&B Bio-Tech (02627) Reports Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1124130150","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124130150?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:42","pubTimestamp":1772444545,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (stock code: 02627) released the monthly return on movements in securities for the period ended 28 February 2026. The total authorized share capital stood at 393.44 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173944245","title":"Innovative Differentiation and Positive Earnings Forecast Set Stage for Davis Double at AB&B BIO-TECH-B (02627)","url":"https://stock-news.laohu8.com/highlight/detail?id=1173944245","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173944245?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:14","pubTimestamp":1772097260,"startTime":"0","endTime":"0","summary":"Following the announcement on January 30th of this year regarding the successful market approval of the nation's first and only trivalent influenza virus subunit vaccine for the entire population,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198738554","title":"Ab&B Bio-Tech (2627) Reports Significant Revenue Growth and Reduced Net Loss for FY2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1198738554","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198738554?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:02","pubTimestamp":1772096535,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (Stock Code: 2627) has issued a profit alert indicating an expected revenue of 446.00 million to 493.00 million renminbi for the year ended December 31, 2025, reflecting a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":69,"code":"91000000","status":"200"}]}}